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have similar to improved prognosis compared with normal or
underweight HF patients, and we maintain that weight reduction
as a therapeutic goal needs to be more closely examined in the
population of advanced HF patients.
We concur that the associations observed in our study and in the
other studies in this area prevent making any firm conclusions
regarding lack of benefit or increased risk of weight loss in
overweight and obese patients with HF. We also noted that even
if obesity is not associated with worse HF survival, weight loss may
be desirable if it results in improved functional capacity and
reduced symptoms. Furthermore, we noted that preoperative
obesity may increase morbidity and mortality with heart transplan-
tation, as well as make it more difficult to find a suitable donor.
With regard to mortality, based on the associations observed in
our study and in the absence of clinical trials demonstrating
benefit, we do not believe raising the possibility that weight loss in
patients with established HF may be an ineffective or even
potentially harmful treatment represents a “sweeping” conclusion.
Because there is potential risk to weight-loss therapies, it does not
seem unreasonable to raise the issue regarding what degree of
benefit, if any, could be expected. Severe calorie restriction in
patients with advanced HF has the potential to worsen cardiac
muscle function (3). In addition, fad diets and pharmacologic
weight-loss agents are associated with risk; for example, the
pro-adrenergic weight-loss agent sibutramine may raise heart rate
and blood pressure (4). Although weight loss may be helpful in the
prevention of coronary artery disease and HF, the data to support
a mortality benefit with weight loss in advanced HF patients is
limited. No randomized controlled trials of weight reduction in
HF powered for clinical end points have been conducted to date.
There is clear and compelling evidence from multiple clinical
trials that medical therapies, including beta-blockers, angiotensin-
converting enzyme inhibitors and aldosterone antagonists, improve
symptoms and prolong survival in patients with severe, chronic HF
(5). We maintain that promotion and implementation of therapies
proven to be life-prolonging take precedence over therapies for
which clinical trial evidence is lacking. Based on the available
evidence we disagree with Lavie et al. that weight reduction is a
treatment for HF until proven otherwise. Clinical trials are clearly
needed to provide definitive guidance. Given the public health
implications, we hope the issues we and Lavie and colleagues have
raised will encourage well-designed clinical trials to address this
important issue. In the absence of definite clinical trial evidence,
physicians should carefully weigh both the potential risks and
potential benefits of weight loss in their overweight and obese HF
patients.
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Ischemic Cardiomyopathy: A Historical Note
I enjoyed reading the recent article on a standardized definition of
ischemic cardiomyopathy by Felker et al. (1). However, I was
somewhat surprised by the fact that the investigators did not make
any reference to the origin of the term “ischemic cardiomyopathy.”
It was George Burch and associates (2) who in 1970 coined the
term “ischemic cardiomyopathy,” which was quite provocative as
well as controversial at the time.
Actually, the concept of ischemic cardiomyopathy dated back
one year earlier when Raftery et al. (3) in England suggested a
cause-and-effect relationship between coronary artery disease and
congestive cardiomyopathy. But the term “ischemic cardiomyop-
athy” was introduced and popularized a year later by Burch et al. in
New Orleans (2). They insisted that “The entity, therefore, should
be accepted and recognized in view of the vast similarities to the
other cardiomyopathies” (2). They emphasized that “ischemic
cardiomyopathy is a true cardiomyopathy” (2).
There have been many systems of classification of cardiomyop-
athy ever since its original description by Brigden in 1957 (4). The
World Health Organization (5) in 1981 classified cardiomyopathy
into hypertrophic, dilated and restrictive types. But from a practical
point of view a more useful classification is an etiologic one to
distinguish between ischemic and non-ischemic varieties, because
the prognosis is quite different. As Felker and associates (1)
mentioned, angiographically diagnosed ischemic cardiomyopathy
with heart failure is associated with a shorter survival than is
non-ischemic cardiomyopathy with heart failure.
We are indebted to Burch et al. (2) for their foresight in
introducing and conceptualizing the term “ischemic cardiomyop-
athy” 32 years before its validation by the Duke Databank (1). As
Burch and associates so aptly stated in 1970, “Early recognition of
coronary artery disease is important so that vigorous and prompt
introduction of all measures available can be instituted to improve
the coronary circulation and prevent the development of muscle
damage or ischemic cardiomyopathy” (2).
Tsung O. Cheng, MD
Department of Medicine
The George Washington University
Medical Center
2150 Pennsylvania Avenue, NW
Washington, DC 20037
PII S0735-1097(02)01801-6
1564 Letters to the Editor JACC Vol. 39, No. 9, 2002
May 1, 2002:1563–5
REFERENCES
1. Felker GM, Shaw LK, O’Connor CM. A standardized definition of
ischemic cardiomyopathy for use in clinical research. J Am Coll Cardiol
2002;39:210–8.
2. Burch GE, Giles TD, Colcolough HL. Ischemic cardiomyopathy. Am
Heart J 1970;79:291–2.
3. Raftery EB, Banks DC, Oram S. Occlusive disease of the coronary
arteries presenting as primary congestive cardiomyopathy. Lancet 1969;
2:1146–50.
4. Brigden W. Uncommon myocardial diseases. The non-coronary car-
diomyopathies. Lancet 1957;2:1179–84.
5. Brandenburg RO, Chazov E, Cherian G, et al. Report of the WHO/
ISFC task force on definition and classification of cardiomyopathies.
Circulation 1981;64:437A–8A.
Is Early Invasive Treatment
of Unstable Coronary Artery Disease
Equally Effective for Both Women and Men?
Lagerqvist et al. (1) are to be congratulated for their recent
elaboration of the findings of FRISC II. I am sure we are all very
interested in reiteration of the fact that women do not benefit as
much as men from an early invasive strategy. I must take issue,
however, with one suggestion that they make. They speculate that
women might have done less well (in fact, women appear to have
done non-significantly worse) with an invasive strategy because of
more advanced age, more frequent diabetes and more frequent
previous myocardial infarctions (MIs). If this were true, then these
groups themselves would have been expected to do less well with
an invasive strategy. In fact, all these groups—over age 65 (risk
ratio [RR] 0.59), diabetics (RR 0.62) and previous MIs (RR
0.86)—appeared to benefit from an invasive strategy (2). The
investigators will surely have to look elsewhere for an explanation
of their tantalizing findings.
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